Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest University of Massachusetts Medical School Stories

2009-02-26 11:01:01

Cutting edge science has finally put to rest a 90-year-old mystery that involved nobility, revolution, murder and the long-romanticized story of a child's escape from the firing squad. Genomic analysis performed at the University of Massachusetts Medical School in cooperation with Institutions of Russian Academy of Science (VIGG) and Academy of Medical Sciences (MHRC) have confirmed that human remains found in the Ural Mountains in July 2007 are indeed those of the two "missing" children of...

eedca1d4a98209c246b547dd083c73ea
2009-01-05 14:41:00

Comprehensive study of Medicaid records finds substance abuse increases the cost of other health problems People with substance abuse disorders cost Medicaid hundreds of millions of dollars annually in medical care, suggesting that early interventions for substance abuse could not only improve outcomes but also save substantial amounts of money, according to a comprehensive study that examined records of nearly 150,000 people in six states. "Substance abuse probably costs Medicaid programs a...

67df6de3e7653e766b8db7b3e13cc2ec1
2008-12-30 13:58:17

Writing chemotherapy orders on the day of administration and improved communication could reduce medication errors Seven percent of adults and 19 percent of children taking chemotherapy drugs in outpatient clinics or at home were given the wrong dose or experienced other mistakes involving their medications, according to a new study led by Kathleen E. Walsh, MD, assistant professor of pediatrics at the University of Massachusetts Medical School, and published in the January 1, 2009 issue of...

2008-12-09 11:00:00

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and the University of Massachusetts Medical School announced results from a preclinical study of a Respiratory Syncytial Virus ("RSV") vaccine candidate. Novavax has licensed exclusive worldwide rights from the University of Massachusetts Medical School to certain technology for the development and commercialization of Paramyxovirus vaccines incorporating certain Virus-Like-Particles ("VLPs"). This vaccine...

2008-12-02 06:30:00

PALO ALTO, Calif., Dec. 2 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced the issuance of United States patent 7,459,547, entitled "Methods and Compositions for Controlling Efficacy of RNA Silencing." The issued patent, which is based on the seminal research of Philip Zamore, Ph.D., the Gretchen Stone Cook Chair of Biomedical Sciences and Professor of Biochemistry & Molecular Pharmacology at...

2008-11-14 09:00:34

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported results for the quarter ended September 30, 2008. Tod Woolf, Ph.D., President and Chief Executive Officer of RXi, commented, "We have continued to expand our research and development programs, further solidifying RXi's position as one of the leading companies focused on a comprehensive RNAi...

2008-11-03 09:00:06

PRINCETON, N.J. and JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Medarex, Inc. and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile Associated Diarrhea (CDAD) successfully met its primary objective. The top-line results from the recently completed multi- center, randomized, double-blind, placebo-controlled...

2008-10-15 09:00:47

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that its 45% owned affiliate RXi Pharmaceuticals Corporation has licensed exclusive worldwide rights from the University of Massachusetts Medical School (UMMS) to certain technology for the oral delivery of RNAi therapeutics. The technology was developed by Dr. Michael Czech, Professor and Chair, Program in Molecular Medicine at UMMS and an RXi...

2008-10-15 09:00:08

RXi Pharmaceuticals has licensed exclusive worldwide rights from the University of Massachusetts Medical School to certain technology for the oral delivery of RNAi therapeutics. Financial terms were not disclosed. The technology was developed by Michael Czech, professor and chair, program in molecular medicine at the University of Massachusetts Medical School (UMMS) and an RXi founder, and Gary Ostroff, professor of molecular medicine at UMMS and an RXi collaborator. RXi intends to work...

2008-10-14 09:00:45

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it has licensed exclusive worldwide rights from the University of Massachusetts Medical School (UMMS) to certain technology for the oral delivery of RNAi therapeutics. The technology was developed by Dr. Michael Czech, Professor and Chair, Program in Molecular Medicine at UMMS and an RXi...